PolyPid Ltd. (PYPD) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Greetings and welcome to Polypeed's second quarter 2025 conference call. At this time, participants are in a listen-only mode. As a reminder, this call is recorded. And I would now like to introduce your host for today's conference, Yuda Liebler from Arts Capital Market. Mr. Liebler, you may begin. Thank you all for participating in Polypeed's second quarter 2025 earnings conference call. Joining me on the call today will be Dikla Chachkis-Axelbrod, Chief Executive Officer of PolyPID, Johnny Misalawin, PolyPID's Chief Financial Officer, and Ori Warschowski, Chief Operating Officer, U.S. of PolyPID. Earlier today, PolyPID released its financial results for the three months ended June 30th, 2025. A copy of the press release is available in the Investors section on the company's website, available at www.polypid.com. I'd like to remind you that on this call, management will make forward-looking statements within the meaning of the federal securities law. For example, management is making forward-looking statements when it discusses DPLEX 100's potential benefits, including its potential to address a significant unmet medical need and to substantially reduce the burden of surgical site infections, improve patient outcomes, and generate meaningful healthcare cost savings. The expected regulatory submissions and their timing, the aim of GLP-1 program and its potential to address significant unmet medical needs in the treatment of metabolic diseases, the company's expected cash runway, and the potential partnership opportunities for DPLEX 100. Forward-looking statements are subject to numerous risks and uncertainties, many of which are beyond the company's control, including the risks described from time to time in its SEC filings. The company's results may differ materiall...